SGLT2 Inhibitor-Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event

被引：3
|
作者：
Tukker, Martijn [1 ]
Bruwiere, Ewout [1 ]
Bos, Sven [2 ]
Caliskan, Kadir [1 ,3 ]
机构：
[1] Erasmus MC Univ Med Ctr Rotterdam, Dept Cardiol, Thoraxctr, Rotterdam, Netherlands
[2] Erasmus MC Univ Med Ctr Rotterdam, Dept Haematol, Rotterdam, Netherlands
[3] Erasmus MC Univ Med Ctr Rotterdam, Dept Cardiol, Room RG 431,Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
来源：
CIRCULATION-HEART FAILURE | 2023年 / 16卷 / 07期
关键词：
adverse drug event; dapagliflozin; erythrocytosis; heart failure; polycythemia;
D O I：
10.1161/CIRCHEARTFAILURE.123.010613
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
According to the current heart failure guidelines, SGLT2 (sodium glucose cotransporter 2) inhibitors are increasingly prescribed in patients with heart failure (HF).1 However, SGLT2-inhibitors are known to increase hemoglobin (Hb) and hematocrit (Ht) levels, but literature on SGLT2-induced erythrocytosis is limited. We provide a case of a patient with chronic HF with severe polycythemia associated with dapagliflozin usage, suggesting the potential importance of hemoglobin and hematocrit monitoring. © 2023 Lippincott Williams and Wilkins. All rights reserved.
引用
收藏
页数：3
相关论文
共 50 条
12345